Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium
Wednesday, September 12, 2018, 8:00 AM - 2:30 PM
The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
The New York Academy of Sciences
Cancer immunotherapies utilize the body’s own immune defenses to kill tumor cells. James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center has dedicated his career to better understanding the immune system and leveraging it to treat cancer. Dr. Allison led the development of ipilimumab, a cancer immunotherapy that targets CTLA-4, a receptor that effectively turns “off” immune cells. By inhibiting CTLA-4, ipilimumab activates the immune response to target and kill cancer cells. Ipilimumab was the first immune checkpoint inhibitor approved by the U.S. Food and Drug Administration, achieving long-standing remission of metastatic melanoma in some cases. Its success has helped to establish immunotherapy as a viable and effective strategy more broadly. For his extensive characterization of immune regulation and development of therapies that have dramatically improved the treatment of certain cancers, Dr. Allison will receive the 2018 Dr. Paul Janssen Award for Biomedical Research.
Similar to ipilimumab, other immune checkpoint inhibitors that activate the immune response to cancer through different molecular targets also have recently been deployed to treat a number of different cancers. Beyond immune checkpoint blockade, the field of immune-oncology has grown to include several therapeutic strategies, currently in various stages of development — including cytokine therapy, cancer vaccines, and harvesting and modifying patients’ immune cells (as in CAR-T treatments). Further studies of the immune response to cancer, and of the dynamics of the broader tumor microenvironment, will aid the development and optimization of these therapies. Work is ongoing to apply immunotherapies to new cancers and patients, to understand how best to use them in combination, and to reduce the risk of potentially dangerous side effects.
This half-day symposium, Cancer Immunotherapy: The 2018 Dr. Paul Janssen Award Symposium, will celebrate the work of Dr. Allison, who will review recent advances. Following his award lecture, fellow prominent scientists will discuss several aspects of cancer immunotherapy, from the basic understanding of immune regulation to the development of therapies in the clinic.
Brigham and Women’s Hospital; Dana-Farber Cancer Institute
Janssen Pharmaceutical Companies of Johnson & Johnson
Memorial Sloan Kettering Cancer Center
September 12, 2018
Registration and Breakfast
Welcome and Introductory Remarks
SESSION I: The Past and the Future of Cancer Immunotherapy
2018 Dr. Paul Janssen Award for Biomedical Research Announcement
Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for Cures
The multiple, non-redundant mechanisms that limit T cell responses offer novel strategies for mobilizing the immune system against cancer. CTLA-4, the best characterized immune checkpoint, inhibits T cell proliferation by blocking the interaction of the costimulatory molecule CD28 with its ligands B7-1 and B7-2 on antigen presenting cells. CTLA-4 antibodies have proven effective against multiple tumor types in pre-clinical and clinical studies. Ipilimumab, an antibody to human CTLA-4, was approved by the FDA in 2011 for late stage melanoma and provides long term survival benefit to ~20% of patients. PD-1, another checkpoint, seems to interfere with T cell antigen receptor mediated signaling. Its two ligands, PD-L1 and PD-L2, are normally expressed on dendritic cells, but many tumor cells express PD-L1. Antibodies to PD-1 and PD-L1 provided objective responses against several tumor types in clinical trials in about 25% of patients. In a phase II trial, combined anti-PD-1 and anti-CTLA-4 provided objective responses in ~50% of late stage melanoma patients. We used high parameter flow cytometry to identify the mostly non-overlapping cellular mechanisms of CTLA-4 and PD-1 blockade, which may partially explain the enhanced effect of their combination. T cell responses to tumor cells appear largely directed toward neoantigens arising from mutational events associated with carcinogenesis. While all tumors with antigens recognizable by the immune system should be targets for checkpoint blockade, tumors with lower mutational burdens (prostate, breast, and kidney cancer) present challenges. Strategies for their treatment will be discussed.
SESSION II: Emerging Approaches in Cancer Immunotherapy
A Single Cell Lens in T-cell Behavior
Cellular circuits are dynamic networks which involve many interacting proteins, responding to multiple stimuli before manifesting a functional phenotypic effect. With rapid developments taking place in cellular immunotherapy, design of synthetic cellular circuit components is becoming more complex and novel techniques are required for assessing how a novel circuit functions, rather then simply if it functions. Whilst functional analysis of engineered cells can provide some insight into the downstream effects of synthetic constructs such as chimeric antigen receptors (CARs), to date signalling analysis has predominantly relied on bulk techniques which average over a large number of cells and are inadequate for visualising network states.
High-dimensional single-cell technologies such as mass cytometry allow simultaneous analysis of dozens of protein epitopes in millions of individual cells, each providing information on co-occurrence of protein or phospho-proteins to form complex distributions which should not be collapsed to mean or median statistics. Using techniques from transportation theory, we describe stimulus-induced changes in phospho-protein expression at single-cell resolution. By exploiting the non-linearity of protein-protein relationships, we describe the strength of signals between proteins and how they change between natural and synthetic circuits under various stimulus conditions.
CARs redirect T-cell immunity against chosen antigens. We sought to clarify signalling circuit states in CAR-T cells. Using single-cell resolution data from over 8x106 cells we explore the circuit changes induced by pre-existing and novel designs of chimeric antigen receptor expressed in abT and gdT cells. CARs exert different influences on T-cell circuits to their native receptor counterparts, in particular through increased signal strength and tonic signalling which is associated with increased exhaustion marker expression.
We also demonstrate that CAR-gdT cells offer an opportunity to overcome on-target off-tumor toxicity which has hampered progress in CAR-abT cell design. Removal of CD3z from the CAR abrogated reduced exhaustion marker expression to baseline and CD3z-free CARs still enhanced gdT cell cytotoxicity against tumor cells expressing their cognate antigen. Excitingly, CD3z-free CAR-gdT cells demonstrated no toxicity against cognate-antigen expressing healthy cells.
Many Faces and Functions of Regulatory T Cells
Regulatory T (Treg) cells represent a specialized lineage of cells of the adaptive immune system, whose biological role is in preserving tissue functions. Treg cells mediate a unique means of negative regulation in-trans of inflammation and, thereby, contain the consequent tissue damage. T cell and interleukin-2 receptor signaling are required for differentiation of Treg cells in the thymus and - in combination with TGF-β signaling - for their extrathymic differentiation. These signals also promote generation of potently suppressive activated “effector” Treg cells in the secondary lymphoid organs and non-lymphoid tissues, which partake in a variety of biological processes ranging from tissue repair and maintenance to suppression of immune responses to “self” and infectious agents to control of metabolite levels and cancer progression. Common and distinct features of Treg cells in diverse physiological and pathological settings and their functions will be discussed.
Coffee and Networking Break
The Potential and Promise of Immunotherapy in Breast Cancer
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Immune checkpoint therapies, including anti-CTLA-4, anti-PD-1 and anti-PD-L1, have led to significant clinical responses in cancer patients. To investigate immunologic changes and mechanistic pathways that are elicited by these therapies, we conducted pre-surgical and tissue-based clinical trials, which permit access to tumor tissues for laboratory studies. To compare and contrast data, we chose one tumor type that responds well to immune checkpoint therapy and one that does not. The first pre-surgical trial was conducted with anti-CTLA-4 (ipilimumab) in a cohort of patients with localized bladder cancer. The second pre-surgical trial was conducted with anti-CTLA-4 (ipilimumab) in patients with localized prostate cancer. In addition, we evaluated data from patients with melanoma who received immune checkpoint therapy. These data enabled us to identify the ICOS/ICOSL pathway as relevant for anti-tumor immune responses in the setting of anti-CTLA-4 therapy. We also identified resistance mechanisms including expression of other immune inhibitory pathways, such as VISTA, and loss of the IFN signaling pathway in tumor cells. These data will be discussed in greater details.
Oncolytic Viruses: Past Present Future
Advanced Bio Design
Aggamin Pharmaceuticals, LLC
Biomedical Research Institute of New Jersey
Boehringer Ingelheim Pharmaceuticals
Brigham and Women’s Hospital, Dana-Farber Cancer Institute
Brooklyn College Department of Chemistry
C Wilmot Consulting, LLC
Columbia University Irving Medical Center
Fortress Biotech, Inc.
Human Microbiology Institute
Hunter College, CUNY
Imclone Systems, Inc.
Janssen Research & Development, LLC
Johnson & Johnson
Jones Trading Institutional Services
Meharry Medical College
Memorial Sloan-Kettering Cancer Center
Merck & Co., Inc.
Montefiore Medical Center
New Jersey City University
New York University Medical Center
NYU Division of Rheumatology
NYU Langone Health
NYU School of Medicine
Pfizer Global Research and Development
Regeneron Pharmaceuticals, Inc
Roche Translational and Clinical Research Center (TCRC)
Rutgers Cancer Institute of New Jersey
Rutgers Graduate School of Biomedical Sciences
Rutgers University Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey
Sanofi Research & Development
Southern Connecticut State University
St. John's University
St. John's University College of Arts and Sciences
SUNY Downstate Medical Center
Temple University School of Medicine
The Albert Einstein College of Medicine
The Damon Runyon Cancer Research Foundation
The Rockefeller University
The Trout Group
The University of Texas MD Anderson Cancer Center
University of La Laguna Tenerife, Spain
University of Texas MD Anderson Cancer Center
Weill Cornell Medicine
West Virginia University